INTERACTIONS OF ATOVAQUONE WITH OTHER ANTIMALARIAL-DRUGS AGAINST PLASMODIUM-FALCIPARUM IN-VITRO

被引：207

作者：

CANFIELD, CJ ^{[1
]}

PUDNEY, M ^{[1
]}

GUTTERIDGE, WE ^{[1
]}

机构：

[1] WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND

来源：

EXPERIMENTAL PARASITOLOGY | 1995年 / 80卷 / 03期

关键词：

PLASMODIUM FALCIPARUM; IN VITRO CULTURE; ANTIMALARIALS; DRUG INTERACTIONS; SYNERGY; ATOVAQUONE; PROGUANIL; TETRACYCLINE;

D O I：

10.1006/expr.1995.1049

中图分类号：

R38 [医学寄生虫学]; Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ; 100103 ;

摘要：

A series of Plasmodium falciparum in vitro drug sensitivity studies were conducted in order to evaluate atovaquone in combination with other antimalarial drugs and thus to identify a potential partner for a fixed combination. The derived isobolograms indicated that drug interactions ranged from antagonism through addition to synergy. Of particular note were the quinolines and artemisinin analogues, which were all antagonistic, and the biguanides and tetracycline, which showed synergy. Proguanil emerged as the most promising of the current antimalarials as a partner for atovaquone in a fixed combination, with tetracycline as back-up. (C) 1995 Academic Press, Inc.

引用

页码：373 / 381

页数：9

共 29 条

[1]

Berenbaum M.C., A method for testing for synergy with any number of agents, Journal of In-Fectious Diseases, 137, pp. 122-130, (1978)

[2]

Brueckner R.P., Milhous W.K., Canfield C.J., Quantitative isobolic analysis of antimalarial drug interactions, “Program and Abstracts of the 40Th Annual Meeting of the American Society of Tropical Medicine and Hygiene." Supplement to American Journal of Tropical Medicine & Hygiene, 45, (1991)

[3]

Canfield C.J., New antimalarials underdevelopment, “Chemotherapy of Malaria, pp. 99-100, (1986)

[4]

Canfield C.J., Canfield K.B., Schuster B.G., Milhous W.K., Does the intrinsic activity of proguanil contribute to its antimalarial efficacy?, 38Th Annual Meeting of the American Society of Tropical Medicine and Hygiene, (1989)

[5]

Canfield C.J., Milhous W.K., Ager A.L., Roosen R.N., Sweeney T.R., Lewis N.J., Jacobus J.P., PS-15: A potent, orally-active antimalarial from a new class of folic acid antagonists, American Journal of Tropical Medicine and Hygiene, 49, pp. 121-126, (1993)

[6]

Canfield C.J., Rozman R.S., Clinical testing of new antimalarial drugs, Bulletin of the World Health Organization, 80, pp. 203-212, (1974)

[7]

Desjardins R.E., Canfield C.J., Haynes J.D., Chulay J.D., Quantitative assessment of antimalarial activity in vitro by a semi-automated microdilution technique, Antimicrobial Agents and Chemotherapy, 16, pp. 710-718, (1979)

[8]

Fry M., Pudney M., Site of action of the antimalarial hydroxynaphthoquinone 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1, 4-naphthoquinone (566C80), Biochemical Pharmacology, 43, pp. 1545-1553, (1992)

[9]

Gutteridge W.E., Chemotherapy, Modern Parasitology, pp. 218-239, (1993)

[10]

Gutteridge W.E., Dave D., Richards W.H.G., Conversion of dihydroorotate to orotate in parasitic protozoa, Biochimica Et Biophysica Acta, 582, pp. 390-401, (1979)

← 1 2 3 →